Ulrich Jäger, MD, from the Medical University of Vienna, Vienna, Austria, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Jäger stresses the need to make CAR T-cell therapy available for a larger plethora of illnesses. He goes on to discuss the importantance of patient selection, due to CAR-T being an expensive treatment it is not only harmful to those that won’t benefit from it but is also not cost-effective.